Advanced glycosylation end products: a new disease marker for diabetes and aging.
Advanced glycosylation end products (AGEs) are a potentially useful marker for monitoring glycemic control, predicting the risk of diabetes- and aging-associated clinical complications, and monitoring the treatment of patients with micro- and macrovascular diseases, including retinopathy, atherosclerosis, nephropathy, and neuropathy. AGEs or AGE-proteins are derived from nonenzymatically glycated proteins (Amadori products) after further cross-linking with other proteins and additional rearrangement. AGE-proteins can be assayed by either radioreceptor or immunoassays in blood and tissues. No commercial kit is available at this time.
Wu
J T
JT
Department of Pathology, University of Utah Medical Center, Salt Lake City 84108.
D000375:Aging / Q000378:metabolism*; D015415:Biomarkers / Q000032:analysis; D003920:Diabetes Mellitus / Q000175:diagnosis / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D017127:Glycation End Products, Advanced / Q000032:analysis*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D011869:Radioligand Assay
D015415:Biomarkers; D017127:Glycation End Products, Advanced; D006454:Hemoglobins